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Liver cirrhosis is one of chronic liver diseases with high disability and mortality accompanying fibrosis, 
hepatocyte damage, and liver dysfunction. In this study, the hepatoprotective and the antifibrotic properties 
of lesimarin(lecithin - silymarin - Artemisia messerschmitiana Besser(AMB) extract complex at 11:3:6 
ratio) on rat hepatic fibrosis induced by thioacetamide (TAA) was investigated. Rats were divided into 
seven groups: control, lesimarin, TAA, TAA+lesimarin, TAA+lecithin, TAA+silymarin, TAA+AMB. Rats 
were administered with TAA at a dose of 200 mg/kg body weight intraperitoneally twice a week for three 
months. Lesimarin, lecithin, silymarin and AMB were administered at a dose of 1.0, 1.0, 0.5, 1.0g/kg 
body weight orally daily for three months, respectively. TAA administration resulted in hepatic fibrosis, 
significant decrease in body weight, albumin level and A/G ratio and increase in plasma transaminase, 
GGT(γ-glutamyltransferase) and ALP(alkaline phosphatase) activities as well as hepatic hydroxyproline 
content, which were attenuated by lesimarin administration. Lesimarin was found to decrease AST, 
ALT and GGT, ALP and bilirubin, hydroxyproline levels and increase albumin level and A/G ratio and 
its effect is more prominent than those of individual constituents. These results suggest this new drug, 
lesimarin, might be a promising drug to be used for chronic liver diseases. 
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INTRODUCTION
The liver disorders are very frequent and widely 
distributed in the world. Among them hepatic fibrosis 
represents the response of the liver to different chronic 
insults, and is associated with significant morbidity and 
mortality. Recent studies have clearly demonstrated 
that the excessive accumulation of extracellular matrix 
in liver fibrotic diseases is a dynamic and bidirectional 
process which is mainly regulated by hepatic stellate cells 
(HSC) (Abul et al., 2002). Several in vitro studies have 
shown that the process of HSC activation results from the 
complex interplay of different factors, such as cytokines, 
growth factors, oxidative stress and modification of 
Na+/H+ exchange activity (Aydin et al., 2010).
In several experimental models for the induction 
of cirrhosis, hepatotoxic agents such as thioacetamide 
(TAA), carbon tetrachloride and ethionine have been 
used. Thioacetamide (TAA) has been widely used for 
experimentally induced liver injury. While acute TAA 
application results in hepatitis, chronic TAA application 
has been shown to cause liver cirrhosis (Chilakapati et al., 
2007). Oxidative stress has been reported to play an 
important role in the pathogenesis of TAA-induced 
hepatitis and cirrhosis. Indeed, several studies have 
demonstrated the beneficial effect of antioxidants 
in protecting the liver against TAA-induced injury 
(Palacios et al., 2008). 
Silymarin extracted from the milk thistle is well 
regarded for its antioxidant and protective effects on the 
liver. It has been shown to protect the liver against increased 
oxidative stress caused by alcohol consumption, CCl4 or 
TAA and accelerate alcohol metabolism (Chen et al., 2012; 
Chung-His et al., 2012).
The elevated levels of liver enzymes such as aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) found in liver injuries and chronic diseases are 
reduced significantly (30–35%) by its use. Silymarin has 
been shown to reduce liver fibrosis up to 30–35%, and in 
few cases it has reversed the liver fibrosis. It has also been 
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reported to have anti-inflammatory, immunomodulatory, 
antiviral and liver-regenerating properties (Adeyemo et al., 
2013; Freedman et al., 2011; Mahmood et al., 2014). It also 
causes an improvement of liver steatosis and inflammation 
by decreasing membrane lipid peroxidation, reducing 
free-radical release and restoration in the GSH levels 
(Carina et al., 2012). In addition, it was found to induce 
reduction of leukotriene formation from unsaturated free 
acid, enhance protein synthesis, stabilize mast cell, inhibit 
cytP450 detoxification system and prevent metabolism 
of toxic compound such as thioacetamide, carbon 
tetracholoride and acetaminophen (Madani et al., 2008).
Lecithin is a group of yellow brownish fatty 
substances occurring in animal and plant tissues, and in 
egg yolk (Korbanjhon, Chungang, 2013; Carina et al., 
2013). Lecithin is the major component of all the cell 
membranes and plays an important role in the normal 
function of the cells. It was found that lecithin stimulated 
bile lipid secretion and prevented a cholestatic effect of 
cyclosporine A -induced reduction of bile flow and an 
alteration of F-actin microfilaments in the liver. And its 
effect might be related to the effect of dietary lipids on 
chemical and physical composition of the hepatocyte 
plasma membrane (Benkoel et al., 2000). On the other 
hand, lecithin is known to prevent fatty liver by ensuring 
triglycerides export out of the liver and as such can be 
considered as promising therapeutic agents in the realm 
of functional foods (Maida, Sugas, Marica, 2012). 
Artemisia messerschmidtiana Besser(AMB) is a 
traditional herb, which contains various kinds of active 
ingredients such as scopoletin, chlorogenic acid, volatile 
oil and β-sitosterol etc. These substances have cholagogic, 
antibacterial, diuretic and hemostatic actions and are 
effective against various organic liver diseases such as 
fatty liver and hepatic necrosis. In addition, it was found 
to increase amount of bile both in the normal rat and rat 
model of liver injury via carbon tetrachloride (CCl4) and 
to decrease serum transaminase activities (Konovalova, 
Rybalko, 1977). Therefore, it has been traditionally used 
in the treatment of various liver dysfunction in several 
Asian countries including our country.
Although a lot of modern medicines are developed, 
discovering a new drug for treating various liver diseases 
remained still as a difficult problem. The pharmacological 
effects of above mentioned individual constituents have 
been reported, but there is no scientific evidence regarding 
the safety and efficacy of them in combination.
The purpose of the present study was to evaluate the 
hepatoprotective and the antifibrotic effects of a new drug, 
Lesimarin(mixture of lecithin, silymarin and Artemisia 
messerschmitiana Besser extract at 11:3:6 ratio).
MATERIAL AND METHODS
Material
TAA and silymarin was purchased from Sigma 
Aldrich (St Louis, MO, USA) and dissolved in sterile 
saline until all the crystals were dissolved. Lesimarin was 
the product of new technical developmental institute, 
Mannyon pharmaceutical company, DPRK. It was made by 
mixing lecithin, silymarin and Artemisia messerschmitiana 
Besser extract at 11:3:6 ratio. Lecithin was obtained from 
Sangon (Shanghai, China) Artemisia messerschmitiana 
Besser collected in suburb of Pyongyang was decocted 
until its humidity is 40% and used in the experiment. HCl 
were obtained from Sigma Aldrich (St. Louis, USA).
Experimental animals and chronic administrations 
of Lesimarin
Wistar rats, aged 8weeks, were obtained from the 
Animal Center of Pyongyang Medical College, Kim Il 
Sung University. The animals were allowed free access to 
food and water and were kept in wire-bottomed stainless 
steel cages. They were maintained in a temperature-
controlled room (25±3 ℃) and kept on a 12h/12h light/
dark. Eighty four animals were divided into seven 
groups: control, Lesimarin(LES), TAA, TAA+Lesimarin, 
TAA+lecithin(LEC), TAA+silymarin(SIL), TAA + AMB. 
Control group received standard laboratory chow. 
TAA group received 200 mg TAA/kg body weight 
intraperitoneally twice a week for three months as in a 
previous paper (Aydin et al., 2010). Lesimarin, lecithin, 
silymarin and AMB were administered to the rats at a 
dose of 1.0, 1.0, 0.5, 1.0 g/kg body weight orally daily for 
three months, respectively. At the end of three months, 
rats were fasted overnight and killed by collecting blood 
into heparinized tubes by cardiac puncture, after which 
analysis of serum biochemistry and liver histopathology 
was performed to confirm chronic liver fibrosis and the 
effect of mixture. 
Isolation of specimens and determination
Body weight, liver size, serum biochemical values 
and histopathological results of the rats in all the groups 
were analysed at the end of the 12 week experiment. 
The body weights of the animals were recorded weekly 
beginning from day 1 and throughout to the end of 
the experiment. The livers of the rats were isolated, 
dissected, and then rinsed in normal saline. Following 
this, the liver was blotted with filter paper and weighed. 
Effect of Lesimarin against thioacetamide-induced liver cirrhosis in rat
Braz. J. Pharm. Sci. 2019;55:e17821 Page 3 / 9
The liver index was calculated as the percentage of the 
body weight.
Blood samples were obtained by intracardiac 
puncture. Serum was separated from blood samples by 
centrifugation at 3000 × g for 10 min. Activities of aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
γ-glutamyl transpeptidase (GGT), alkaline phosphatase 
(ALP) and total protein(T-protein) were determined using 
commercial enzymatic kits with a SPOTCHEM TM EZ 
SP-4430 biochemistry analyser (ARKRAY, Inc., Kyoto, 
Japan), as described previously (Chen et al., 2012).
Liver hydroxyproline content was determined 
by using liver specimens (100-250 mg) which were 
homogenized in buffer and hydrolyzed in 2 mL 6 N HCl 
at 110 ℃ for 24 h. After that the hydrolysis samples were 
treated and quantified spectrophotometrically at 565 nm 
using a colorimetric analyser (Dri-Chem 3000, Fuji Photo 
Film Co, Tokyo, Japan) (Switzer et al., 1991).
Histopathological analysis 
Hepatic morphology was assessed by light 
microscopy. Liver tissue (i.e. 1 cm × 1 cm × 0.5 cm) was 
taken from the largest right lobe of the liver and fixed 
in 10% of formalin solution for 1 week. The liver tissue 
was dehydrated using a sequence of ethanol solutions, 
embedded in paraffin and sectioned to 5 μm in thickness at 
50 mm intervals followed by staining with hematoxylin–
eosin (HE) dye. Masson’s trichrome stain was used for the 
observation of liver fibrosis. (Shaker et al., 2011).
Statistical analysis
All results are expressed as mean±SD (standard 
deviation). Differences between other groups were tested 
by using analysis of variance (ANOVA). Where significant 
effects were found, T-test was performed. p < 0.05 was 
considered to be significant. 
RESULTS AND DISCUSSION
Liver fibrosis represents a major medical problem 
with significant morbidity and mortality. It is the common 
response to chronic liver injury, ultimately leading to 
cirrhosis and its complications, portal hypertension, liver 
failure, and hepatocellular carcinoma (Bataller, Brenner, 
2005). TAA-induced liver fibrosis is an ideal model to 
test potential antifibrotic drugs because the hepatotoxin 
TAA is well known to produce a hardly reversible fibrosis 
in rodents similar to that of humans (Laleman, Vander, 
Zeegers, 2006).
In the present study, there was a statistically significant 
reduction of body weight in rats administered with TAA 
compared to the normal and lesimarin-treated groups. This 
reduction in body weight could strongly be attributed to the 
toxic effect of TAA throughout the period of the experiment. 
This is considered to be the most reliable and consistent 
symptoms of toxicity among the experimental animals 
(Ljubuncic et al., 2005). Although there was an increase 
in body weight in TAA+LES, TAA+LEC, TAA+SIL, 
TAA+AMB group compared with TAA group, but there 
was no significant difference between them. Concurrently, 
the liver to body weight ratio showed a corresponding 
significant difference between all treated groups compared 
to TAA group. The increase in body weight of rats treated 
only with Lesimarin is similar to that of the normal control 
group. The result revealed that Lesimarin has a tendency to 
normalize the liver function (Table I).
Our experimental data also showed a damage of liver 
tissue during TAA-administration for 12 weeks.
TAA-induced damage of liver can be linked to 
TAA-metabolism by hepatic CYP2E1 to TAA-sulfoxide, 
TABLE I - Body weight and liver weights of the rats in different groups
Group Body weight (g) Liver weight (g) Liver index (%)
Control 217.80 ± 13.68* 6.85 ± 0.73* 3.18 ± 0.41*
LES 223.51±13.59* 6.91 ± 0.71* 3.09 ± 0.37*
TAA 175.32 ± 7.51# 8.25 ± 0.95# 4.75 ± 0.56#
TAA+LES 202.24 ± 12.53 7.03 ± 0.81 3.36 ± 0.45*
TAA+LEC 189.36 ± 10.32 7.20 ± 0.76 3.75 ± 0.48*
TAA+SIL 198.75 ± 12.24 7.06 ± 0.82 3.63 ± 0.28*
TAA+AMB 184.54 ± 9.87 7.32 ± 0.83 3.86 ± 0.51*
The data were stated as mean ± SD. Means with different superscripts are significantly different. * P < 0.05 versus TAA group and 
# P < 0.05 versus TAA+LES group. LES stands for Lesimarin. TAA stands for thioacetamide. LEC, SIL, AMB stand for lecithin, 
silymarin, Artemisia messerschmitiana Besser, respectively.
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and to the highly reactive TAA-sulfdioxide that is 
responsible for TAA-induced hepatotoxic effects. During 
TAA-metabolism, both flavin-containing monooxygenase 
and cytochrome P450 reduce dioxygen to O2·, which is 
catalyzed to form H2O2. H2O2 may generate the highly 
reactive hydroxyl radical (·OH) by the Fenton reaction, 
which is responsible for enhanced lipid peroxidation 
(Shaker et al., 2011).
In the present study, we found that a 12-week 
regimen of Lesimarin can improve the symptoms of 
hepatic fibrosis induced by TAA. All drug-treated groups 
showed significant decrease of plasma ALT and AST 
levels compared with TAA-treated rats, but the effects of 
other individual constituents of mixture are not so potent 
as that of Lesimarin indicating the benefit of new drug 
(Table II). Enzymes such as ALT and AST are often used 
as biochemical markers of hepatic injury. In damaged 
liver cells, the ALT and AST leak into the blood stream, 
leading to an increase in the plasma levels. Thus elevation 
of plasma AST and ALT activities in the serum could be 
regarded as an index of damage of the liver parenchyma 
cells (Ching Yang et al., 2013). Lesimarin lowered GGT, 
ALP, total bilirubin level significantly compared with 
TAA-group (Table III). The toxic effect of TAA was 
also alleviated by the individual constituents of mixture, 
of which extents are inferior to lesimarin. GGT, ALP 
activities indicate the function of epithelial cells of biliary 
duct and it is elevated in the case of biliary tract diseases. 
Total bilirubin level also shows the function of hepatic 
cells and the state of bile excretion. These results suggest 
that Lesimarin could improve the bile duct function. 
Albumin level and A/G ratio were increased in all 
drug-treated groups compared with TAA-treated group, 
but there was no difference in total protein level between 
all treated groups (Table IV). And TAA+LES group 
showed more remarkable effect on albumin level and 
A/G ratio compared with those of individual constituents. 
Reduced level of albumin usually shows the severity of 
the condition, and it is a reliable index of the prognosis. 
Generally, the continuation of hypoalbuminaemia 
indicates a progress or a change to a chronic state (Thapa, 
Walia, 2007). The significant improvement at the level 
of biochemical parameters is indicative of the beneficial 
effects of Lesimarin in protecting the liver.
Grossly, the liver surfaces of the TAA group showed 
many spots of nodules, relatively harder in comparison 
with the normal gross features of the livers from the 
control (Figure 1A, 1B). In contrast to this, the livers from 
TAA+Lesimarin group were with much fewer nodular 
spots, softer in consistency, and with a comparatively 
normal liver size than the TAA group although the liver 
TABLE II - Effect of TAA, Lesimarin and its constituents on 
AST, ALT activities








The data were stated as mean ± SD. Means with different 
superscripts are significantly different. * P < 0.05 versus TAA 
group and # P < 0.05 versus TAA+LES group. LES stands for 
Lesimarin. TAA stands for thioacetamide. LEC, SIL, AMB stand 
for lecithin, silymarin, Artemisia messerschmitiana Besser, 
respectively.
TABLE III - Effect of TAA, lesimarin and its constituents on GGT, ALP activities and bilirubin level
Group GGT (U/L) ALP (U/L) Bilirubin(mg/dL)
Control 1.23±0.46*# 152.1±18.9*# 0.48±0.10*
LES 1.30±0.41*# 147.2±15.4*# 0.45±0.08*
TAA 8.32±2.67# 318.2±31.9# 1.27±0.33#
TAA+LES 3.13±1.76* 197.2±20.3* 0.59±0.15*
TAA+LEC 5.82±2.42*# 241.3±23.7*# 0.91±0.23*#
TAA+SIL 5.23±2.05*# 232.5±21.6*# 0.79±0.18*#
TAA+AMB 4.77±1.86*# 226.6±19.8*# 0.84±0.26*#
The data were stated as mean ± SD. Means with different superscripts are significantly different. * P < 0.05 versus TAA group 
and # P < 0.05 versus TAA+LES group. GGT stands for γ-glutamyltransferase. ALP stands for alkaline phosphatase.LES stands 
for Lesimarin. TAA stands for thioacetamide. LEC, SIL, AMB stand for lecithin, silymarin, Artemisia messerschmitiana Besser, 
respectively. 
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could not restore the deep red color of the normal control 
group (Figure 1C). 
The appearance of HE-stained liver following 12 
weeks of TAA and the result of lesimarin treatments are 
shown in Figure 2. Microscopic examinations in the present 
study showed that the severe liver damage induced by TAA 
could be significantly reduced by the administration of 
lesimarin. Livers from TAA-treated groups showed loss 
TABLE IV - Effect of TAA, lesimarin and its constituents on total protein, albumin and A/G ratio
Group T-protein(g/dL) Albumin(g/dL) A/G
Control 7.35±0.46 4.02±0.49* 1.20±0.19*#
LES 7.38±0.43 3.99±0.44* 1.17±0.18*#
TAA 7.09±0.28 1.89±0.26# 0.36±0.08#
TAA+LES 7.29±0.41 3.68±0.38* 0.96±0.13*
TAA+LEC 7.20±0.35 2.78±0.37*# 0.65±0.10*#
TAA+SIL 7.27±0.38 3.15±0.32*# 0.81±0.11*#
TAA+AMB 7.16±0.33 2.45±0.28*# 0.52±0.09*#
The data were stated as mean ± SD. Means with different superscripts are significantly different. * P < 0.05 versus TAA group 
and # P < 0.05 versus TAA+LES group. A/G stands for the ratio of albumin to globulin. LES stands for lesimarin. TAA stands for 
thioacetamide. LEC, SIL, AMB stand for lecithin, silymarin, Artemisia messerschmitiana Besser, respectively. 
FIGURE 1 - Photographs showing the macroscopic appearances of livers from different groups: (A) control group-showing regular 
smooth surface, (B) TAA group-showing liver with multiple cirrhotic nodules on the whole surface of the liver, (C) TAA+Lesimarin-
showing liver similar to normal with a smooth surface.
FIGURE 2 - Pictures showing the histopathological images of livers from different experimental groups (A)TAA group-showing 
marked vacuolar degeneration and fibrosis (B)TAA+LES group-showing mild vacuolation. Hematoxylin-Eosin stain. Magnification 
×200.
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of normal architecture with the presence of regenerating 
nodules separated by prominent fibrous septa extending 
from the central vein and marked vacuolar degeneration 
(Figure 2A). Compared with the lesions observed in the 
TAA group, the lesions of the Lesimarin-treated rats were 
of a much milder degree. These animals showed slight to 
moderate diffuse necrosis and vacuolations of hepatocytes 
(Figure 2B). This is in correlation with the results of the 
liver functional parameters on lesimarin-treated group. 
On the other hand, TAA-treated rats showed 
an increase in hepatic levels of hydroxyproline. Oral 
administration of lesimarin for 12 weeks produced a 
significant reduction in hepatic levels of hydroxyproline 
in TAA-treated rats (Figure 3). 
And there was remarkable reduction in the extent 
of fibrosis, which is probably due to reduced amount of 
stellate cells infiltration in rats treated with Lesimarin 
compared to TAA group microscopically. By using 
Masson’s trichrome stain, it was found that the nodules 
of hepatocytes were separated only by thin fibrous septa 
in the lesimarin-treated group, in contrast by thick and 
remarkable fibrous septa in TAA group (Figure 4). 
The improvement of TAA-induced hepatic fibrosis 
by lesimarin might be related to the lowering of fibrotic 
parameters such as hydroxyproline. Hydroxyproline is 
a common non-proteinogenic amino acid (Ostergaard, 
Holm, 1997). It is found only in collagen and elastin 
in mammals. Hydroxyproline is formed only by a post-
FIGURE 3 - Effect of TAA, lesimarin and its constituents on hydroxyprolin level. The data were stated as mean ± SD. Means with 
different superscripts are significantly different. * p < 0.05 versus TAA group and # p < 0.05 versus TAA+LES group. LES stands 
for Lesimarin. TAA stands for thioacetamide. LEC, SIL, AMB stand for lecithin, silymarin, Artemisia messerschmitiana Besser, 
respectively.
FIGURE 4 - Pictures showing the histopathological images of livers from different experimental groups: (A)TAA group-showing 
epithelial proliferation of bile duct and thick fibrous septa, (B)TAA+LES group-showing thin fibrous septa and mild epithelial 
proliferation of bile duct, Masson’s trichrome stain. Magnification ×200.
Effect of Lesimarin against thioacetamide-induced liver cirrhosis in rat
Braz. J. Pharm. Sci. 2019;55:e17821 Page 7 / 9
translational modification in the peptide chain, and 
proline hydroxylase does not hydroxylate free proline. 
Hydroxyproline levels in tissue hydrolysates are a direct 
measure of the amount of collagen or gelatin present 
(Colgrave et al., 2012). A variety of disease states are 
believed to affect collagen turnover and can cause elevated 
serum or urine hydroxyproline levels. Such conditions 
include neoplastic, inflammatory, hepatic and autoimmune 
disorders. Thus, a reduction of hepatic hydroxyproline was 
considered for the attenuation of hepatic fibrosis (Li et al., 
2011). In our results, lesimarin and silymarin lowered the 
hepatic hydroxyproline level in TAA-induced hepatic 
fibrosis showing an attenuation of hepatic fibrosis. And 
the other ingredients of mixture showed no significant 
improvement on hydroxyproline level compared with 
TAA group (Figure 3). That means silymarin is much 
more important than the rest constituents of the mixture 
in preventing liver fibrosis. 
All our findings indicated lesimarin might be a 
protective agent against liver diseases such as liver 
cirrhosis. The injured liver cells stimulate hepatic stellate 
cells to transform into myofibroblast-like cells, which 
secrete large amount of collagen, thereby producing liver 
fibrosis. Activation of HSCs is also regarded as a major 
cause of liver fibrosis. HSC activation generates the alpha 
smooth muscle actin (α-SMA)-positive myofibroblast-
like cells that are responsible for scar tissue formation 
in the fibrotic liver. On the other hand, the induction of 
free radical generation, mitochondrial dysfunction and 
depletion of antioxidants are effective in the progression 
of fibrosis and cirrhosis (Aydin et al., 2010; Chen et al., 
2012).
A previous acute toxicity study showed nontoxic 
property of lesimarin, and the LD50 dose recorded was over 
20g/kg body weight. In addition, there were no histological 
changes in liver, heart, and kidney in any of the doses of 
the lesimarin. This is consistent with our findings on the 
various parameters as shown in tables and figures.
Silymarin, a constituent of mixture, causes down-
regulation of MMPs (matrix metalloproteinases), TGF-
β1(transforming growth factor beta 1), α-SMA(alpha 
smooth muscle actin) and COL-α1(collagen alpha 1) 
on TAA-induced chronic liver fibrosis. MMPs are zinc- 
and calcium-dependent proteases that participate in the 
degradation of extracellular matrix (ECM) molecules. 
Major components of the ECM in liver fibrosis include 
collagen types I, III and IV. MMP-2, MMP-8, MMP-9 
and MMP-13 cause fibrinolysis and tissue remodelling, 
which results in the progression of liver fibrosis. And 
theses enzymes are expressed on the HSCs. TAA-induced 
liver damage observed in the present study may be due to 
MMP up-regulation and HSCs activation (Visse, Nagase, 
2003). Such an activation and proliferation of HSCs 
which promote cell proliferation, collagen deposition and 
fibrogenesis is also inhibited by silymarin administration 
(Abenavoli et al., 2011; Michaela, Gerry, Miles, 2015; 
Sario et al., 2005). In addition, it is well known to be 
safe in animal models and possess potent antioxidant and 
hepatoprotective properties by contributing to reduced 
lipid peroxidation, increased liver glutathione level and 
stabilization of the membrane permeability (Abouzeinab, 
2013; Chen et al., 2012).
Lecithin is an important component of cell 
membranes and forms ultrastructure of mitochondria 
and microsomes and is recognized as an indispensable 
substance for the maintenance of various enzyme 
activities. Lecithin is related to the architecture of 
membranes and microgranules of the hepatic cells and 
membrane permeability and the enzyme activities. It is 
also associated with the energy-producing system and 
oxidative phosphorylation in the mitochondria. Some 
researchers have proved that phopholipid-containing drugs 
are effective in the treatment of liver diseases. Lecithin 
also improves lipid metabolism in the liver and prevents 
the exacerbation of liver diseases. It has been used as a 
matrix to improve the lipophilic property and targeted 
delivery of bioactive compounds. It has been reported that 
silymarin has poor water solubility and bioavailability, but 
lecithin makes it 10 times more bioavailable (Korbanjhon, 
Chungang, 2013; Michaela, Gerry, Miles, 2015). This 
property of lecithin appears to contribute to the better 
effect of mixture than individual constituents.
Besides Artemisia messerschmidtiana Besser 
extract has remarkable cholagogic action, thereby 
showing positive action against the diseases of liver and 
biliary tract. It is well known to decrease AST and ALT 
activities in the various animal models associated with 
liver diseases. Lecithin and Artemisia messerschmidtiana 
Besser extract are supposed to help the hepatoprotective 
action of silymarin through their actions on the liver. 
CONCLUSIONS
From the above observations, it can be concluded 
that lesimarin was effective in attenuating liver fibrosis 
induced by TAA as evidenced by histological and 
biochemical analyses. It is shown to have more potent 
hepatoprotective effect as compared with its individual 
constituents, that suggests the superiority of combination. 
Accordingly, this drug could be used as an effective 
product for the prevention and treatment of chronic liver 
diseases including hepatic cirrhosis.
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